MedinCell S.A. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was EUR 9.89 million compared to EUR 4.09 million a year ago. Net loss was EUR 29.5 million compared to EUR 24.81 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.7 EUR | -5.91% | -11.04% | +90.28% |
May. 15 | Medincell: share price falls after disappointing clinical study | CF |
May. 14 | Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+90.28% | 428M | |
+32.36% | 694B | |
+30.77% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.77% | 239B | |
+9.13% | 209B | |
-3.97% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- MEDCL Stock
- News MedinCell S.A.
- MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023